Canada: Pharma In Brief - Federal Court Grants One Of Three Prohibition Applications For VIGAMOX® Eye Drops Containing Moxifloxacin Hydrochloride

Case: Alcon Canada Inc. et al. v. Cobalt Pharmaceuticals Company et al.
Drug: Moxifloxacin hydrochloride [VIGAMOX®]
Nature of case: Prohibition Application pursuant to PM(NOC) Regulations
Successful party: Divided success
Date of decision: May 4, 2014


This latest decision from the Federal Court is consistent with a recent trend towards a more literal construction of patent claims.  The Court preferred not to broaden the promise of the patent and instead adopted a construction that fairly reflects the intention of the inventor based on a plain reading of the text of the patent.

Alcon Canada Inc., Alcon Pharmaceuticals Ltd. and Bayer Intellectual Property GmbH GP ("Alcon") brought an application pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Cobalt Pharmaceuticals Company ("Cobalt") in respect of a generic version of the drug VIGAMOX®.  VIGAMOX® is the most commonly used antibacterial eye drop containing the medicinal ingredient moxifloxacin hydrochloride.  It is covered by Canadian Patent Nos. 1,340,114 (the "'114 Patent), 2,342,211 (the "'211 Patent") and 2,192,418 (the "'418 Patent").

The Court allowed Alcon's application for a prohibition order with respect to the '114 Patent, which claims a class of compounds of which moxifloxacin is one.  The Court found that Cobalt's allegation of invalidity on the basis of obviousness and a lack of sound prediction and utility was not justified.

The Court dismissed Alcon's application for a prohibition order with respect to the '211 Patent, which claims certain uses for moxifloxacin, and the '418 Patent, which claims the monohydrate form of moxifloxacin.  The Court found that Cobalt's allegation of obviousness with respect to the '211 Patent was justified and that Cobalt's allegation of non-infringement of the '418 Patent was justified.

The '114 Patent – Genus patent which includes claims for moxifloxacin

Claim Construction

The '114 Patent claims a novel class of quinolones distinguished by a fused pyrrolidine bicycle at the C-7 position of the quinolone ring.  This class of compounds is said to have high antibacterial activity, particularly against Gram-positive bacteria.  The specific compound moxifloxacin and its enantiomers are claimed in Claims 8 and 13 of the '114 Patent.  The Court rejected Cobalt's submission that a single reference to low toxicity in the '114 Patent and a list of possible bacteria that can be treated with the class of compounds were essential elements of every claim.  

Utility/Sound Prediction

The Court began its utility analysis by considering whether the inventors of the '114 Patent made a specific promise.   The Court held that to the extent the '114 Patent promises anything, it is limited to a promise that the class of quinolones as a whole will have in vitro activity against a broad spectrum of bacteria.  The Court rejected Cobalt's reliance on a single reference to low toxicity in the patent and a list of pathogens and medical conditions that may be treated by the class of quinolone compounds as forming part of the promise.  If the inventors had intended to make these promises, the patent would have been drafted to make the promise more explicit.  The Court held that references to low toxicity and pharmaceutical uses are descriptions of hopes or potential uses, not promises.

Since moxifloxacin was not synthesized or tested prior to the filing date of the '114 Patent, the utility of moxifloxacin was based on a sound prediction.  The factual basis for the prediction of utility of the claims to moxifloxacin is the Maximum Inhibitory Concentration [MIC] test results in the '114 Patent for Example 15.  Moxifloxacin is not an Example compound in the '114 Patent although it closely resembles Example 15 except for having a different substituent at the C-8 position on the quinolone ring.  The Court accepted that it was common general knowledge that the substituent at the C-8 position of moxifloxacin was expected to retain high activity and that the effect of chirality which is further from the quinolone core has little impact on activity.  As such, Alcon argued and the Court accepted that the inventors had a sound basis for predicting that moxifloxacin had at least the same if not higher antibacterial activity than the compound  in Example 15 of the '114 Patent.


Cobalt alleged that the public's right to disclosure was denied in the '114 Patent because, like the patent in Teva Canada Ltd. v. Pfizer Canada Inc., 2012 SCC 60, the '114 Patent claims millions of compounds but obscures the identity of moxifloxacin.  The Court rejected Cobalt's submissions.  The Court found no evidence that the inventors of the '114 Patent excluded information from the patent for an improper purpose or that they intentionally misled the public.  Further, there was no evidence before the Court that certain compounds were inactive.  Finally, to the extent that there were some minor discrepancies between the data provided for the example compounds in the '114 Patent and the compounds tested in lab notebooks, these discrepancies were not sufficient to invalidate the patent.


The parties agreed that the inventive concept of the '114 Patent is the claimed compounds' unique fused pyrrolidine bicycle at the C-7 position of the quinolone ring and accompanying high antibacterial activity.  Cobalt argued that the choice of modifying the C-7 position on the quinolone ring was obvious and that the choice of a fused pyrrolidine bicycle substituent was obvious.  The Court rejected both of these positions.

The Court held that numerous prior art references showed that many other positions on the quinolone ring were being investigated for antibacterial activity and that there was nothing in the art suggesting that a fused pyrrolidine bicycle conferred enhanced antibacterial activity.  The Court was also persuaded by the actual course of conduct that culminated in the invention, including the extensive work in making hundreds of compounds annually with modifications at nearly all positions on the quinolone ring.  As such, the Court concluded that Cobalt's allegation of obviousness had not been made out.

The '211 Patent – Claims uses for moxifloxacin

Claim Construction

The '211 Patent claims the use of moxifloxacin in a concentration of between 0.1 to 1.0 wt% as an antibiotic agent in a pharmaceutical composition for use in the treatment and prevention of ophthalmic infections.  It further claims the pharmaceutical composition itself, and the use of the composition for topically treating or preventing ophthalmic infections.


The Court held that the inventive concept of the '211 Patent is a pharmacological composition for topically treating or preventing an ophthalmic infection, which comprises 0.1 to 1.0 wt% of moxifloxacin.  In light of the common general knowledge as of the priority date of the '211 Patent, the Court found that the use of moxifloxacin in a topical ophthalmic formulation for the treatment of bacterial infections was obvious or obvious to try.  The Court's finding was primarily based on the fact that Ciprofloxacin, another quinolone antibiotic, was sold commercially in solution for the treatment and prevention of ocular infections, as were other quinolones such as Ofloxacin.  Therefore, it was obvious to try to treat ophthalmic infections with moxifloxacin.  

According to the Court, the claims of the '211 Patent were directed to a known compound being used for a known use in a concentration known to be effective.  As such, Cobalt's allegation of invalidity on the basis of obviousness was justified and the Court dismissed Alcon's prohibition application in respect of the '211 Patent.

The '418 Patent – Claims monohydrate form of moxifloxacin

Claim construction

The '418 Patent claims the monohydrate form of moxifloxacin having two characteristic peaks, which is said to have improved stability over the anhydrous form.  It also claims the prism crystal form of moxifloxacin monohydrate, which is said to be more free-flowing than the needle crystal form.  The Court held that Claim 1 of the '418 Patent contained three essential elements: (1) the compound moxifloxacin monohydrate; (2) the compound displays a characteristic band in the powder X-ray diffractogram at 2Ɵ = 26.7; and (3) the compound displays a characteristic peak in the 13C-NMR spectrum at 168.1 ppm.  The Court rejected Alcon's argument that it only needed to show that Cobalt's product had either a characteristic band or a characteristic peak but not both.


The parties accepted that Cobalt's finished product did not infringe the '418 Patent.  Alcon argued that Cobalt infringed the '418 Patent through its manufacturing of its moxifloxacin product and based its argument that Cobalt's process uses moxifloxacin monohydrate on the data provided in Cobalt's ANDS.  The Court held that while Cobalt's ANDS is suggestive of a process that uses moxifloxacin monohydrate, including XPRD data which showed the characteristic band claimed in the '418 Patent, there was no 13C-NMR data available regarding Cobalt's process.  Since the 13C-NMR characteristic peak is an essential element of Claim 1 of the '418 Patent, the Court held that infringement had not been established on the evidence.

The Court declined to draw an inference, in the absence of actual evidence from Cobalt's process, that because the other elements of Claim 1 have been met, it necessarily follows that a characteristic peak at 168.1 ppm would be present in Cobalt's process. The Court held that a possibility of infringement is not enough to rebut the presumption of the truth of the allegations contained in a Notice of Allegation.  The Court stated at para. 230: "Whatever the criticism of Cobalt for not producing 13C-NMR data, it was Alcon's burden to do as much as reasonably possible to establish infringement.  In my view, they did not do so and did not advance a good reason for not putting forward the best evidence."  The Court was not prepared to accept assumptions from experts when better objective evidence could have been produced.  As such, Cobalt's allegation of non-infringement of the '418 Patent was found to be justified.

Link to decision

Alcon Canada Inc. v. Cobalt Pharmaceuticals, 2014 FC 462

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.